VR Logo

Halozyme Therapeutics Inc. (HALO) download report


Healthcare | Biotechnology & Pharma Research

Halozyme Therapeutics Inc. (HALO) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.

IPO Date: 16-Mar-2004

Pres, CEO & Director: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.

Sr. VP & Chief Technical Officer: Dr. Michael J. LaBarre

Listing: NASDAQ: HALO

Country: United States

Headquarters: San Diego, CA

Website: https://www.halozyme.com

Key Facts

Market cap: $6,136.02 Mln

Revenue (TTM): $471.57 Mln

Earnings (TTM): $434.92 Mln

Cash: $786.14 Mln

Total Debt: $877.65 Mln

Insider's Holding: 1.05%

Liquidity: Low

52 Week range: $31.36 - 48.54

Shares outstanding: 137,950,000

10 Years Aggregate:

  • CFO: $105.37 Mln
  • EBITDA: $83.56 Mln
  • Net Profit: $101.54 Mln

Stock Performance

Time Period Halozyme Therapeutics (HALO) S&P BSE Sensex S&P Midcap 400
YTD10.62-9.18-19.22
1 month-7.91-4.78-8.89
3 months11.53-9.66-14.77
1 Year-2.050.81-14.84
3 Years37.3110.335.68
5 Years28.2511.345.62
10 Years17.5111.749.32
As on 01-Jul-2022
Year Halozyme Therapeutics (HALO) S&P Midcap 400 S&P BSE Sensex
2021-5.8523.2121.99
2020140.8911.8115.75
201921.1924.0514.38
2018-27.66-12.435.87
2017105.0614.4527.91
2016-42.9918.731.95
201579.59-3.71-5.03